Advertisement

Topics

Latest "Texas Center Proton Therapy" News Stories

19:02 EDT 19th September 2018 | BioPortfolio

Here are the most relevant search results for "Texas Center Proton Therapy" found in our extensive news archives from over 250 global news sources.

More Information about Texas Center Proton Therapy on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Texas Center Proton Therapy for you to read. Along with our medical data and news we also list Texas Center Proton Therapy Clinical Trials, which are updated daily. BioPortfolio also has a large database of Texas Center Proton Therapy Companies for you to search.

Showing "Texas Center Proton Therapy" News Articles 1–25 of 15,000+

Extremely Relevant

RaySearch Laboratories: Tsuyama Chuo Proton Beam Center, Japan, Teats First Patients With RayStation

The proton center opened in 2016 and is run jointly with Okayama University. It is equipped with Mitsubishi Electric's proton therapy system, featuring the SELECTBEAM Read more...


Proton beam therapy finally arrives in UK

28 years after the US first pioneered proton beam therapy at Loma Linda University Medical Center, the UK now has its own centre that will be able to provide this type of treatment to patients. The high-energy proton beam therapy will be available via a private clinic in Newport, Wales, after the company behind it receiving funding from the Welsh Government. Image caption:  ...

First proton imaging system to be installed in NHS high energy proton beam therapy center

(University of Lincoln) One of the most complex medical imaging systems ever developed which uses proton beams to create 3D images of the internal anatomy of cancer patients will be installed in one of the UK's only two new NHS high energy proton beam therapy centres, helping to provide better treatment planning and monitoring for difficult to treat cancers.


New mode of proton therapy for lung cancer developed by Beaumont shows promising results

"Beaumont researchers have invented a new mode of proton therapy for lung cancer," said Peyman Kabolizadeh, M.D., Ph.D., clinical director, Beaumont Proton Therapy Center in Royal Oak.

Japan Proton Therapy Market Research Report 2018 [Report Updated: 13022018] Prices from USD $1100

The report titled Japan Proton Therapy Market Research Report 2018 examines the market dynamics, competitive landscape and discusses major trends. The report offers the most uptodate industry data on the actual and potential market situation, and future outlook for proton therapy in Japan. The research includes historic data from 2012 to 2017 and forecasts until 2025. Longterm Growth Projection: ...

Proton Therapy Market – Forecasts from 2018 to 2023 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Proton Therapy Market – Forecasts from 2018 to 2023” report has been added to ResearchAndMarkets.com’s offering. The global proton therapy market is anticipated to witness a compound annual growth rate of 4.03% during the forecast period to reach … Continue reading → Cet article Proton Therapy Market – Forecasts from...

Proton Therapy Trials 'at Risk,' Slow to Enroll Patients

Is proton therapy better than standard radiotherapy in the treatment of cancer? Seven major randomized clinical trials have no answers at this point. Medscape Medical News

IBA and RaySearch to display first online adaptive proton therapy workflow at ESTRO

RaySearch, the global leader in software for cancer treatment, and IBA, the world’s leading provider of proton therapy solutions for the treatment of cancer, will make a unique joint presentation at the ESTRO 37 Annual Meeting. The companies will demonstrate their innovative approach to optimizing the patient treatment workflow through the first online adaptive proton therapy workflow.

Relevant

Tsuyama Chuo Hospital in Japan commences clinical use of RayStation

Tsuyama Chuo Hospital in Okayama Prefecture, southwest Japan, has commenced clinical use of RayStation to plan pencil beam scanning treatments at its Proton Beam Cancer Center. On 15 May, the center carried out the world’s first patient treatment using RayStation together with Mitsubishi Electric’s proton therapy system, with a plan created in RayStation 6.

Why randomized trials for proton therapy are difficult to complete (and what we can do about it)

(University of Pennsylvania School of Medicine) Commercial insurance medical policies that do not cover treatment with proton therapy can make it difficult for patients to participate in randomized clinical trials funded by the NCI, part of the National Institutes of Health, that are evaluating the therapy.

Combining Proton Beam Therapy and Immunotherapy

Are outcomes improved in patients with NSCLC receiving both proton beam therapy and immunotherapy? Translational Lung Cancer Research

Proton-Beam Therapy: Snags in US but Expanding Globally

While some proton-beam therapy centers in the United States have hit financial snags, the global market is growing, with centers popping up all over the map. Medscape Medical News

Global Proton Therapy Market Outlook 2022 [Report Updated: 11012018] Prices from USD $1050

Proton beam therapy or proton therapy, part of particle therapy is the most advanced form of radiation therapy with precise dose sculpting and efficiency. It is an external beam radiotherapy using photon ionizing radiation to irradiate tumors. It successfully eradicates sideeffects associated with other forms of conventional radiation therapies for destroying cancer cells. The proton therapy syste...

Genprex Updates Agreement with University of Texas MD Anderson Cancer Center

Genprex (NASDAQ:GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that it has amended its agreement with The University of Texas MD Anderson Cancer Center to resume patient enrollment in its Phase I/II clinical trial evaluating the combination of the company’s investigational … Cont...

Provision CARES Proton Therapy Treats 2,000th Patient with Most Advanced Form of Cancer Treatment

Provision CARES Proton Therapy Center, a non-profit medical provider in Knoxville, Tennessee, reached a milestone by treating the 2,000th patient with proton therapy. Opening on January 20, 2014, Provision has positively impacted thousands of patients and their family members by offering the most advanced treatment option available, proton therapy. “It...

Researchers find combination can enhance ipilimumab immunotherapy

(University of Texas M. D. Anderson Cancer Center) Using a targeted therapy to block a protein that suppresses T cell activity could improve cancer treatment with immune checkpoint inhibitors, researchers at The University of Texas MD Anderson Cancer Center report today in the Journal of Clinical Investigation.

New Texas supercomputer to push the frontiers of science

(University of Texas at Austin, Texas Advanced Computing Center) The National Science Foundation announced today that it has awarded $60 million to the Texas Advanced Computing Center at the University of Texas at Austin for the acquisition and deployment of a new supercomputer that will be the fastest at any US university and among the most powerful in the world. The new system, known as Frontera...

Mevion Raises $150 Million from China Investors for Proton Therapy Machines

Mevion Medical Systems, a Boston area maker of proton therapy machines, closed a $150 million financing led by YuanMing Capital with participation by other China-based private equity investors. Mevion said the financing provides the company with growth capital, clears existing debt and "optimizes" the shareholder structure. The company believes its proton systems offer a smaller footprint, lower o...

Mendelsohn shares Tang Prize for leadership in developing targeted therapy

(University of Texas M. D. Anderson Cancer Center) Targeted cancer therapy pioneer John Mendelsohn, M.D., researcher and former president of The University of Texas MD Anderson Cancer Center, will share the 2018 Tang Prize in Biopharmaceutical Science for his leadership in developing antibodies to block cancer-promoting growth factor receptors on the surface of cancer cells.

First-in-human clinical trial of new targeted therapy drug reports promising responses for multiple

(University of Texas M. D. Anderson Cancer Center) A phase I, first-in-human study led by The University of Texas MD Anderson Cancer Center reveals for the first time, an investigational drug that is effective and safe for patients with cancers caused by an alteration in the receptor tyrosine kinase known as RET. The drug appears to be promising as a potential therapy for RET-driven cancers, such ...

Gilbane Building Company Tops Out at UF Health Proton Therapy

The expansion and upgrade of three existing gantries enables the treatment of more patients JACKSONVILLE, Fla. (PRWEB) May 02, 2018 Gilbane Building Company, a national leader in the construction of proton therapy facilities, celebrated the milestone of topping out the concrete at the UF Health Proton Therapy Institute Gantry Expansion Project. The ceremony was attended by UF Health Proton Therap...

Global Proton Therapy Market Outlook 2021 [Report Updated: 21122016] Prices from USD $800

Proton beam therapy or proton therapy, part of particle therapy is the most advanced form of radiation therapy with capability to precisely localize radiation dosage. It is an external beam radiotherapy which makes use of focused ionizing radiation. It is highly advantageous as it successfully eradicates sideeffects associated with other forms of conventional radiation therapies for destroying can...

Lonza opens world’s largest gene therapy manufacturing plant in Texas

Swiss drug manufacturer Lonza has opened a ‘state-of-the-art’ cell and gene therapy manufacturing facility, the Lonza Houston Center of Excellence....Read More... The post Lonza opens world’s largest gene therapy manufacturing plant in Texas appeared first on Pharmaceutical Technology.

Supercomputer simulations show new target in HIV-1 replication

(University of Texas at Austin, Texas Advanced Computing Center) Nature study found naturally-occurring compound inositol hexakisphosphate (IP6) promotes both assembly and maturation of HIV-1. NSF-XSEDE allocations on the Stampede2 supercomputing system at the Texas Advanced Computing Center and on Anton2 at the Pittsburgh Supercomputing Center simulated atomistic interactions of IP6 molecule with...

Genprex Amends Options to License Additional Cancer Fighting Technologies from MD Anderson Cancer Center

AUSTIN, Texas & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Genprex, Inc. (NASDAQ: GNPX), a clinical stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, announced today that it has entered into amendments with The University of Texas MD Anderson Cancer Center (MD Anderson) to extend the terms of two option agreements ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks